Regulus Therapeutics is a San Diego-based biopharmaceutical company focused on developing microRNA-targeted drugs for orphan kidney diseases, including its candidate RGLS8429 for autosomal dominant polycystic kidney disease. The company went public on October 4, 2012, and has 28 employees.
Joseph P Hagan bought 50,000 shares of RGLS on 30 January at $1.09 per share, worth a total of $54K. They now own 260,808 RGLS shares, or a 24% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
